Plate Nº 64 · recorded November 18, 2026
Health & Medicine ResearchReported finding
A Common Gut Antibody May Hold the Key to Preventing Colon Cancer
Rockefeller University scientists found that mice lacking IgA, a common gut antibody, develop more than twice as many colon tumors — and oral IgA restored protection.
By Priya Raman3 min read621 words
In brief
- Mice lacking IgA developed more than twice as many colon tumors as normal mice (Nature, November 11, 2026)
- Oral IgA supplementation eliminated the increased cancer risk in deficient mice
- IgA deficiency affects roughly 1 in 500 Americans and is linked to higher colorectal cancer risk
- IgA restrains intestinal cell growth by binding the DMBT1 receptor on epithelial cells
- The research was funded by NIH grants including R01CA218133 and U54CA261701

Mice lacking a single common gut antibody developed more than twice as many colon tumors as mice with normal antibody levels, according to a study published November 11, 2026, in Nature. When researchers at Rockefeller University gave the deficient mice immunoglobulin A by mouth, the increased cancer risk disappeared entirely.
The finding may explain a long-standing puzzle in human health: why people with IgA deficiency (a condition in which the body produces too little of this antibody, affecting roughly 1 in 500 Americans) face a heightened risk of colorectal cancer.
"One intriguing aspect of this work is that it shows how a natural defense in the gut restrains the cell division that can lead to cancer," said Daniel Mucida, senior author of the study and head of Rockefeller's Laboratory of Mucosal Immunology. "Most cancer research focuses on trying to destroy a tumor that already exists, but what if we could intervene before tumors form?"
What did the experiments show?
Immunoglobulin A, or IgA, is one of the immune system's first lines of defense in the digestive tract. Unlike antibodies that target one specific pathogen, IgA can bind to many kinds of gut bacteria and even to some healthy human cells. Scientists have long known that these antibodies are abundant in the gut, yet their full purpose has remained unclear.
Gregory Donaldson, a former Rockefeller postdoctoral fellow who is now an assistant professor at UCLA, tested whether IgA's interactions with gut bacteria could explain its link to cancer. He compared mice lacking IgA with normal mice raised alongside them, ensuring both groups encountered the same food and the same germs.
The elevated cancer risk appeared across several different mouse models of colon cancer. More significantly, the researchers detected changes in genes controlling cell division before any tumors had formed, which suggests IgA shapes cancer risk at the earliest stage of the disease.
How does the antibody put the brakes on cell growth?
The team traced the effect to a molecule called DMBT1, a receptor sitting on the surface of intestinal cells. Gabriella Lima dos Reis, a graduate student in Gabriel Victora's laboratory, helped identify its role.
In the presence of gut bacteria, DMBT1 encourages intestinal cells to multiply. IgA acts as a brake: it binds to the receptor and limits that growth. Without the antibody, the signal can run unchecked, allowing cells to divide excessively and eventually form tumors. Removing the gut bacteria, or switching off DMBT1 signaling, also prevented the uncontrolled growth.
"If IgA is missing, epithelial cells that are performing their normal function—responding to bacteria by producing new cells—can keep dividing unchecked, leading to cancer," Mucida said. "We think this homeostatic effect is IgA's main function. This was a big surprise."
Could this lead to prevention in people?
The discovery points toward two possible strategies, though both remain speculative for now.
- Targeting the pathway after polyp removal. Polyps (small growths in the intestinal lining) increase the likelihood of developing colon cancer. Mucida believes intervening in the IgA–DMBT1 pathway could lower that risk for patients who have had polyps removed.
- Protective probiotics. Donaldson notes that although much research has focused on microbes that encourage tumor growth, some bacteria may help protect intestinal cells. One possibility is developing probiotics that stimulate protective IgA responses.
The study, funded by grants from the National Institutes of Health (including R01CA218133, R01AI165570, R01AI157137 and U54CA261701), has not established a cancer-prevention treatment for humans, and the mouse results may not translate directly to people. Still, the work suggests that understanding how gut bacteria, antibodies and intestinal cells interact could open new opportunities to stop colon cancer before it starts.
For now, the brake exists only in mice.
via google.com (Original)
More from Priya Raman
Show full bio
Senior reporter covering people, launches and day-to-day practice in general science news at SciBeat.
476 articles
Nearby plates
- 'Unhealthy' Diets Made Immunotherapy Work Better — in Mice
- Johns Hopkins Team Finds the Docking Point a Gut Toxin Uses to Attack the Colon
- IBD food reactions may stem from gut bacteria loss, study finds
- Some High-Fat Diets Boosted Immunotherapy in Mice, McGill Study Finds
- Two Gatekeeper Proteins Guide Immune Cells' Risky DNA Mutations